Jo 1 Antibodies, IgG, Serum
Evaluating patients with signs and symptoms compatible with a connective tissue disease, especially those patients with muscle pain and limb weakness, concomitant pulmonary signs and symptoms, Raynaud’s phenomenon, and arthritis
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Jo 1 (histidyl tRNA synthetase) is a member of the amino acyl-tRNA synthetase family of enzymes found in all nucleated cells. Jo 1 antibodies in patients with polymyositis bind to conformational epitopes of the enzyme protein and inhibit its catalytic activity in vitro.(1)
Jo 1 antibodies are a marker for the disease polymyositis, and occur most commonly in myositis patients who also have interstitial lung disease. The antibodies occur in up to 50% of patients with interstitial pulmonary fibrosis and symmetrical polyarthritis.(2)
See Connective Tissue Disease Cascade (CTDC) in Special Instructions and Optimized Laboratory Testing for Connective Tissue Diseases in Primary Care: The Mayo Connective Tissue Diseases Cascade in Publications.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
<1.0 U (negative)
> or =1.0 U (positive)
Reference values apply to all ages.
A positive result for Jo 1 antibodies is consistent with the diagnosis of polymyositis and suggests an increased risk of pulmonary involvement with fibrosis in such patients.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Testing for antibodies to Jo 1 is not useful in patients with a negative test for antinuclear antibodies.
A negative test for Jo 1 antibodies does not exclude the diagnosis of polymyositis or dermatomyositis.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Targoff I: Autoantibodies in polymyositis. Rheum Dis Clin North Am 1992;18:455
2. Leff R, Sherman J, Plotz P: Inflammatory muscle diseases. In Clinical Immunology Principles and Practice, Second edition. Edited by R Rich, T Fleisher, W Shearer, B Kotzin, et al. St. Louis, Mosby-Year Book, 2001, Chapter 65, pp 65.1-65.8